Trastuzumab monotherapy

Breast Cancer Research and Treatment

Volumn 81, Issue SUPPL. 1, 2003, Pages

  Vogel, Charles ^a,b  

^a Cancer Research Network Inc   (United States)

^b Cancer Research Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG DISEASE; METASTASIS; MONOTHERAPY; ONCOGENE NEU; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE;

EID: 0344010617     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1026325008419     Document Type: Conference Paper

References (4)

1. Baselga J, Tripathy D, Mendelsohn et al.: Phase II study of weekly, intravenous, recombinant, humanized anti-p185 Her-2 monoclonal antibody in patients with Her 2/neu overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744, 1996
2. Cobleigh MA, Vogel CL, Tripathy D et al.: Multinational study of the efficacy and safety of humanized anti-Her-2 monoclonal antibody in women who have Her-2 - overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999
3. Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first line treatment of Her-2 overexpressing metastatic breast cancer. J Clin Oncol 120: 719-726, 2002
4. Carbonell-Castellon X, Casteneda-Soto NJ, Clemens M et al.: Efficacy and safety of 3 weekly Herceptin monotherapy in women with Her-2 positive metastatic breast cancer: preliminary report from a phase II study. Proc Am Soc Clin Oncol 21: 19a, 2002 (abstract 73)